Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results

Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results
Data on cariprazine, an investigational antipsychotic agent, includes additional details from a Phase III trial for acute mania in bipolar I disorder and results from an open-label extension study in schizophrenia. Separately, data on levomilnacipran, …
Read more on MarketWatch (press release)

APA Announces New Changes to Drafts of the DSM-5, Psychiatry's New “Bible”
… period (or less if successfully treated): Throughout the book, similarly organized lists of symptoms follow the names of every officially recognized mental disorder—bipolar disorder, autistic disorder, generalized anxiety disorder and so on.
Read more on Scientific American (blog)

Comments Off

Filed under Bipolar Disorder Treatment

Comments are closed.